NewsPremune enters agreement with Dechra for distribution of the company’s licensed products in North America

In January, Premune extended its collaboration with Dechra Veterinary Products for distribution of Redonyl® Ultra on the North American market. Sales in the US and Canada are scheduled to start in the first half of 2018.

Redonyl® Ultra is a supplement in the premium segment for dogs and cats with the patented ingredient Palmitoylethanolamide (shortened PEA, a body-type fatty acid with natural anti-inflammatory properties).

Premune licensed the global rights for the product (outside Italy) in 2015 from local Italian actor Innovet Italia. In 2017, sales began in Europe, in partnership with Dechra. The launch has been successful, and Redonyl® Ultra is today sold in several important markets, including Britain, Germany, Spain and the Nordic region. In 2017, Premune has received orders worth just over SEK 8 million.

Premune now extends its cooperation with Dechra and has entered into distribution agreement for the North American region. Redonyl® Ultra is an excellent addition to Dechra’s wide portfolio of dermatology products, offering veterinarians a holistic approach to managing itching.

The United States is the world’s largest market for animal health products. The partnership with Dechra is strategically important to quickly build up large sales volumes on this new geography. With over 70 selles people, primarily focused on dermatology, Premune believes that Dechra has what it takes to successfully introduce Redonyl® Ultra on the North American market.

For more information please contact:
Viktor Karlsson
CEO
+46 760 265 269
viktor@premune.com